BCL9 and neoplasm: In addition, anti-PD-1 therapy achieved a greater decrease in MC38 tumor growth of Bcl9/Bcl9l deficiency mice than those of Bcl9f/fBcl9lf/f mice as well as increased the survival in Bcl9f/fBcl9lf/f Cre-ERT2 mice (TGI = 92.3%, Fig. 8c, d).